Ultragenyx Sold Priority Review Voucher for $210 Million
The company monetized a regulatory voucher following FDA approval for its gene therapy, GENGLYCOS.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do government priority review voucher programs effectively encourage the development of rare disease therapies?
Ultragenyx has sold a Rare Pediatric Disease Priority Review Voucher for $210 million. The voucher was awarded after the FDA approved the company's GENGLYCOS gene therapy for glycogen storage disease type Ia.
Why it matters
The sale provides significant capital to fund future rare disease therapy development. The FDA created this program to incentivize companies to bring new drug products for rare pediatric conditions to market.
The voucher was generated following the FDA approval of GENGLYCOS, a gene therapy designed to treat glycogen storage disease type Ia. The transaction is currently pending the expiration of the Hart-Scott-Rodino waiting period.
The players
Ultragenyx
This is a biopharmaceutical company that focuses on the development of novel therapies for rare and ultra-rare genetic diseases.
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs.
The details
The FDA awards these vouchers to sponsors that successfully secure approval for treatments targeting rare pediatric diseases. Companies may use these vouchers to receive priority review for subsequent drug applications or choose to sell them to generate liquidity.
Timeline
October 13, 2026: The sale of the voucher was publicly reported.
The Tech Race
This transaction follows the framework set by the FDA's Rare Pediatric Disease Priority Review Voucher program, which serves as a major financial incentive for biotech innovation. It illustrates how regulatory milestones are increasingly leveraged as strategic capital assets in the modern pharmaceutical industry.
While this sale primarily strengthens the financial position of Ultragenyx to pursue future projects, it demonstrates the high market value placed on FDA regulatory speed. For the broader industry, it shows how gene therapies like GENGLYCOS provide long-term commercial pathways for rare disease treatments.
The takeaway
Companies can use these regulatory vouchers to bridge the high costs of drug development by securing non-dilutive capital. Investors often watch these sales as indicators of a firm's commitment to sustaining a pipeline of rare disease treatments.
Further reading
Learn more about the latest industry developments in the Biotech section.
Source note: This article includes information reported by BioXconomy.
Live Poll
Do government priority review voucher programs effectively encourage the development of rare disease therapies?
